303 related articles for article (PubMed ID: 16643633)
1. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
[TBL] [Abstract][Full Text] [Related]
3. Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitary adenoma.
Sasagawa Y; Tachibana O; Nakagawa A; Koya D; Iizuka H
J Clin Neurosci; 2015 Mar; 22(3):601-3. PubMed ID: 25455737
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
Ogan K; Berger M; Ball R
J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
[No Abstract] [Full Text] [Related]
5. Intracranial metastatic prostate carcinoma presenting as intermittent double vision.
Saito Y; Kondo Y; Shimizu H; Kunimoto K; Nishimura T
Urology; 2004 Sep; 64(3):589-90. PubMed ID: 15351603
[TBL] [Abstract][Full Text] [Related]
6. [Two cases of non-functional gonadotroph adenoma pituitary apoplexy following GnRH-agonist treatment revealing gonadotroph adenoma and pseudopituitary apoplexy after GnRH administration].
Hernandez Morin N; Huet D; Hautecouverture M
Ann Endocrinol (Paris); 2003 Jun; 64(3):227-31. PubMed ID: 12910066
[TBL] [Abstract][Full Text] [Related]
7. Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
Doyle-Lindrud S
Clin J Oncol Nurs; 2006 Oct; 10(5):565-6. PubMed ID: 17063610
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
9. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
10. Gn-RH antagonist possible response, after Gn-RH agonist failure in a man with metastatic prostate cancer.
Rocco B; Ferrari M; Scardino E; Matei DV; Verweij F; Varela R; De Cobelli O
Anticancer Res; 2005; 25(1B):577-8. PubMed ID: 15816630
[TBL] [Abstract][Full Text] [Related]
11. Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists.
Sinnadurai M; Cherukuri RK; Moses RG; Nasser E
J Clin Neurosci; 2010 Sep; 17(9):1201-3. PubMed ID: 20605467
[TBL] [Abstract][Full Text] [Related]
12. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
Van Poppel H; Klotz L
Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
[TBL] [Abstract][Full Text] [Related]
14. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
15. Apoplexy of clinically silent pituitary adenoma during prostate cancer treatment with LHRH analog.
Błaut K; Wiśniewski P; Syrenicz A; Sworczak K
Neuro Endocrinol Lett; 2006 Oct; 27(5):569-72. PubMed ID: 17159826
[TBL] [Abstract][Full Text] [Related]
16. [Prostatic cancer with cystic formation: a case report].
Kubo M; Taguchi K; Fujisue H; Ihara H; Ikoma F
Hinyokika Kiyo; 1998 Dec; 44(12):883-6. PubMed ID: 10028435
[TBL] [Abstract][Full Text] [Related]
17. Pituitary apoplexy induced by gonadotropin-releasing hormone (GnRH) agonist administration for treatment of prostate cancer: a systematic review.
Raj R; Elshimy G; Jacob A; Arya PVA; Unnikrishnan DC; Correa R; Myint ZW
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2337-2347. PubMed ID: 34156518
[TBL] [Abstract][Full Text] [Related]
18. Advanced prostate cancer with extremely low prostate-specific antigen value at diagnosis: an example of high dose hook effect.
Akamatsu S; Tsukazaki H; Inoue K; Nishio Y
Int J Urol; 2006 Jul; 13(7):1025-7. PubMed ID: 16882082
[TBL] [Abstract][Full Text] [Related]
19. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
Mizusawa H; Kontani K; Okaneya T; Yoneyama T
Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
[TBL] [Abstract][Full Text] [Related]
20. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report].
Segawa N; Inamoto T; Ibuki N; Mizutani Y; Azuma H; Tsuji M; Katsuoka Y
Hinyokika Kiyo; 2010 Jan; 56(1):49-54. PubMed ID: 20104011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
